M&A news

Clearmind Medicine Acquires Charging Robotics for $2.5M

Clearmind Medicine Acquires Charging Robotics for $2.5M

AcquisitionUSD2,500,000Technology, Information and Media

Get the full Charging Robotics ! company profile

Access contacts, investors, buying signals & more

Open in Dashboard
Charging Robotics ! logo
Acquired

Charging Robotics !

Technology, Information and Media

Deal value

USD2,500,000

September 8, 2026

Clearmind Medicine logo
Acquirer

Clearmind Medicine

Clearmind Medicine has acquired Charging Robotics, a developer of wireless charging solutions for electric vehicles, in a deal valued at $2.5 million. The transaction, structured as a full acquisition, transfers ownership of Charging Robotics’ technology and operations to Clearmind, which will integrate the business as a wholly owned subsidiary.

Clearmind Medicine, a biopharmaceutical company focused on treatments for alcohol use disorder and other central nervous system conditions, is entering the EV infrastructure space through this purchase. Charging Robotics has been developing inductive charging systems designed to eliminate physical connectors, targeting both passenger and commercial vehicle applications. The acquired technology is intended to complement Clearmind’s broader investment strategy, which has included exploring adjacent industrial sectors beyond its core drug development pipeline.

The rationale for the acquisition centers on diversification. Clearmind’s primary revenue stream remains tied to clinical-stage research, which carries long timelines and regulatory uncertainty. By absorbing Charging Robotics, the company gains access to a product line with nearer-term commercial potential in the growing electric vehicle market. For Charging Robotics, the deal provides the capital and corporate infrastructure needed to advance its prototypes toward production, a step that would have been difficult to achieve independently given the capital intensity of automotive supply chains.

Under the terms of the agreement, Clearmind will fund ongoing development of the wireless charging systems while retaining the existing engineering team. The combined entity will operate with two distinct divisions: pharmaceutical research and EV charging hardware. Management has indicated that the two units will remain operationally separate, with shared administrative support to control costs.

The acquisition positions Clearmind to generate non-dilutive revenue from the EV sector, which could help fund its clinical programs without additional equity raises. Success will depend on whether the wireless charging technology can secure commercial partnerships with vehicle manufacturers or fleet operators, a hurdle that has challenged many early-stage charging firms. If those partnerships materialize, the subsidiary could become a meaningful contributor to the parent company’s financial profile within two to three years.

No buying signals identified yet.

Unlock GTM signals

Discover Charging Robotics !'s tech stack and active buying intent.

View GTM signals

Unlock key decision-makers

Get direct access to the decision-makers at Charging Robotics !.

Unlock decision-makers